{"nctId":"NCT00603473","briefTitle":"A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures","startDateStruct":{"date":"2008-01"},"conditions":["Epilepsies, Partial"],"count":92,"armGroups":[{"label":"gabapentin","type":"EXPERIMENTAL","interventionNames":["Drug: gabapentin"]}],"interventions":[{"name":"gabapentin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese male or females, ages 3-15 years old at acquisition of informed consent, 15 years old or less at the baseline visit\n* Seizures are classified as simple partial, complex partial or partial becoming secondarily generalized (defined according to the International League Against Epilepsy)\n* Have not been able to achieve adequate seizure control with antiepileptic drugs\n\nExclusion Criteria:\n\n* Seizures related to drugs or acute medical illness\n* History of any serious medical or psychiatric disorder\n* Diagnosis or history of a structural CNS lesion or an encephalopathy shown to be progressive","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures","description":"The Response Ratio calculated by the following equation was assessed as the primary endpoint: R Ratio = (T-B) / (T+B) where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.158","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder Rate","description":"Responder Rate was defined as the percentage of subjects with a 50% or greater reduction in the seizure frequency per 28 days for the 12-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Seizure Frequency (PCH)","description":"PCH calculated by the following equation was assessed as secondary endpoint: PCH = 100 (T-B) / B where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":89},"commonTop":["Somnolence","Nasopharyngitis","Influenza","Fall","Diarrhoea"]}}}